Silynxcom Secures Order from a Naval Force for Combat-Proven Headset Technology

Orion Corporation (OEC) reported interim Phase III results showing that darolutamide, combined with ADT and RT, reduced the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. The 4-year metastasis-free survival rate was 95% compared to 88%. Darolutamide is not yet approved for this use.

Eli Lilly (LLY) presented Phase 1 data for its investigational drug sofetabart mipitecan (Sofe-M) plus bevacizumab, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. The study included 33 patients, with responses consistent across FRα expression levels and prior PARP inhibitor exposure. Sofe-M is being studied in multiple Phase 3 trials under the FRAmework-01 program.

Eli Lilly's experimental drug, sofetabart mipitecan (Sofe-M), showed promising results in a Phase 1 study for ovarian cancer, with a 100% disease control rate in patients. Sofe-M, an FRα-targeting antibody-drug conjugate, is being studied in multiple Phase 3 trials. The company aims to address the unmet need in platinum-sensitive ovarian cancer treatment.

Immatics N.V. (IMTX) reported updated clinical trial data for IMA402 and IMA203CD8. IMA402 showed a 32% cORR and 91% 1-year OS in advanced melanoma patients. IMA203CD8 achieved a 55% cORR in gynecologic cancers with a median DOR of 8.4 months. Both treatments demonstrated favorable safety profiles. The data were presented at the ESMO 2026 meeting.

BlockchAIn Digital Infrastructure (AIB) announced a $1B+ lease strategy for its first data center development, anchored by Nebius. The 12-year lease includes 50 MW IT load, with initial construction expected in 10 months. The company plans to use customer prepayments and project-level debt for funding. AIB also has additional projects in Texas and other states, targeting 200-300 MW under contract by year-end.

Netflix laid off 1,000 employees, including top executives like Bela Bajaria, due to slow subscriber growth and content quality concerns. The company's release strategy and cancellation of shows have been criticized. New chief content officer Peter Rice is expected to improve content quality.